Oncolytic therapy using measles virus [81] and antibody therapy blocking CCR4 [82] or CD30 [83] also lead to increased survival in NOD/SCID and NOG mice inoculated with ATLL or HTLV-1 infected cells. The gene discussed is CCR4; the disease is adult T-cell leukemia/lymphoma.